Description of Medical ServiceTisagenlecleucel (Kymriah®) is an autologous, murine anti-CD19 Chimeric Antigen Receptor T cell (CAR-T) therapeutic process, involving harvesting, modifying, expanding and re-infusing a patient's own immune T-cells, to target and destroy certain cancerous cells. This therapy is used when patients do not respond to other treatment, such as chemotherapy, or relapse.
Description of Medical ConditionAcute lymphoblastic leukaemia is the malignant proliferation of lymphoid progenitor cells in the bone marrow.
Reason for ApplicationFollowing consideration by MSAC at its November 2018 and March 2019 meetings, and an out-of-session meeting in April 2019, the committee supported funding of tisagenlecleucel (Kymriah®) for treatment of acute lymphoblastic leukaemia in paediatric and young adult patients (pALL) as a highly specialised therapy through the National Health Reform Agreement (NHRA). A condition of MSAC’s support was that a full review of the clinical effectiveness, cost-effectiveness and budget impact would be provided to MSAC by the applicant after a specified amount of time had passed from the therapy being made available. In addition to the submission from the applicant, the Department has also invited States and Territories, as suppliers and joint funders of the treatment to provide submissions to the review.
Further information about the NHRA is available at www.health.gov.au/our-work/2020-25-national-health-reform-agreement-nhra
Previous Application Number1519
Consultation SurveyMSAC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application. Please send feedback on this application to commentsMSAC@health.gov.au
MSAC consultation input closed Friday, 9 June 2023.
For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process
Public Summary DocumentPublic Summary Document (PDF 1205 KB)
Public Summary Document (Word 741 KB)